KIORA PHARMACEUTICALS INC R&D Expense

Quick Answer

KIORA PHARMACEUTICALS INC reported R&D Expense of $10.78 million for fiscal year 2025.

KIORA PHARMACEUTICALS INC R&D Expense — Annual History

Fiscal Year R&D Expense YoY Change
2025 $10.78M +37.5%
2024 $7.84M +94.7%
2023 $4.03M +16.8%
2022 $3.45M -35.5%
2021 $5.35M +50.0%
2020 $3.57M -33.8%
2019 $5.39M -33.1%
2018 $8.06M -22.0%
2017 $10.33M +22.7%
2016 $8.42M +210.0%
2015 $2.72M +411.6%
2014 $531.1K

Quarterly R&D Expense

Quarter Ending R&D Expense YoY QoQ
September 30, 2025 $2.73M +24.9% +5.4%
June 30, 2025 $2.59M +26.4% +2.3%
March 31, 2025 $2.53M +50.3% +15.9%
September 30, 2024 $2.18M +101.4% +6.7%
June 30, 2024 $2.05M +47.2% +21.6%
March 31, 2024 $1.68M +284.3% +55.2%
September 30, 2023 $1.09M -18.6% -22.1%
June 30, 2023 $1.39M +145.4% +217.6%
  • KIORA PHARMACEUTICALS INC showed an increase of +37.5% in R&D Expense compared to the prior fiscal year.
  • Over the 2014–2025 period, KIORA PHARMACEUTICALS INC’s r&d expense has grown by 1929.8% (from $531.1 thousand to $10.78 million).
  • The most recent figure is from KIORA PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment